{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:17:26Z","timestamp":1784204246383,"version":"3.55.0"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The objective of the study was to compare the efficacy and safety of oral paricalcitol with oral calcitriol for treating secondary hyperparathyroidism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted the first multicenter open\u2010labelled parallel group randomized controlled trial in 66 patients on dialysis. Patients were randomized to paricalcitol or calcitriol at a 3:1 dose ratio and adjusted to maintain intact parathyroid hormone (<jats:styled-content style=\"fixed-case\">iPTH<\/jats:styled-content>) level between 150\u2013300\u2009pg\/mL, serum calcium \u22642.74\u2009mmol\/L and calcium\u2010phosphate product \u22645.63\u2009mmol<jats:sup>2<\/jats:sup>\/L<jats:sup>2<\/jats:sup>. The primary end point was the proportion of patients who achieved &gt;30% reduction in <jats:styled-content style=\"fixed-case\">iPTH<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 24 weeks, 22 (61.1%) patients in the paricalcitol and 22 (73.3%) in the calcitriol group had achieved the primary end\u2010point (<jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.29). The cumulative proportion of patients who achieved the end\u2010point at 6 weeks, 12 weeks and 24 weeks were 50%, 80.6% and 86.1%, respectively, in paricalcitol and 53.3%, 86.7% and 86.7%, respectively, in the calcitriol group (<jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.67). Median time to the end\u2010point was 6 weeks in both groups. There were no significant differences in <jats:styled-content style=\"fixed-case\">iPTH<\/jats:styled-content> level at any time during the study. The median reduction in <jats:styled-content style=\"fixed-case\">iPTH<\/jats:styled-content> at 24 weeks was 48.4% in the paricalcitol group and 41.9% in the calcitriol group (<jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.6). The median maximal <jats:styled-content style=\"fixed-case\">iPTH<\/jats:styled-content> reduction was 77.1% (paricalcitol) and 83.7% (calcitriol), <jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.3. Serum calcium and incidence of hypercalcaemia did not differ between groups. 16.7% of patients in both groups had at least one episode of hypercalcaemia (serum calcium &gt;2.74\u2009mmol\/L). Other adverse events were similar between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study suggests that oral paricalcitol has similar efficacy and safety to oral calcitriol.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nep.12029","type":"journal-article","created":{"date-parts":[[2013,1,14]],"date-time":"2013-01-14T02:29:02Z","timestamp":1358130542000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism"],"prefix":"10.1111","volume":"18","author":[{"given":"Loke Meng","family":"Ong","sequence":"first","affiliation":[{"name":"Penang Hospital  Georgetown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punithavathi","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Penang Hospital  Georgetown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heong Keong","family":"Goh","sequence":"additional","affiliation":[{"name":"Penang Hospital  Georgetown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Bhajan","family":"Manocha","sequence":"additional","affiliation":[{"name":"Seberang Jaya Hospital  Seberang Jaya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ghazali","sequence":"additional","affiliation":[{"name":"Kuala Lumpur Hospital  Kuala Lumpur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahanim","family":"Omar","sequence":"additional","affiliation":[{"name":"MARA University of Technology  Penang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukeri","family":"Mohamad","sequence":"additional","affiliation":[{"name":"RP Zainab II Hospital  Kota Bharu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bak\u2010Leong","family":"Goh","sequence":"additional","affiliation":[{"name":"Serdang Hospital  Kajang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Shah","sequence":"additional","affiliation":[{"name":"TAR Hospital  Kelang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Ramli","family":"Seman","sequence":"additional","affiliation":[{"name":"TA Afzan Hospital  Kuantan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indralingam","family":"Vaithilingam","sequence":"additional","affiliation":[{"name":"Taiping Hospital  Taiping"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozina","family":"Ghazalli","sequence":"additional","affiliation":[{"name":"Penang Hospital  Georgetown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korina","family":"Rahmat","sequence":"additional","affiliation":[{"name":"Melaka Hospital  Melaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Shaariah","sequence":"additional","affiliation":[{"name":"T. Jaafar Hospital  Seremban"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Hua","family":"Ching","sequence":"additional","affiliation":[{"name":"S. Bahiyah Hospital  Alor Setar Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Oral Paricalcitol in ESRD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002009"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197211022871801"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111639"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2002.122819"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109398"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28110"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19\u2010Nor\u20101\u2010alpha\u201025\u2010dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin KJ","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28114"},{"issue":"4","key":"e_1_2_6_11_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am. J. Kidney Dis."},{"issue":"113","key":"e_1_2_6_12_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2010MBD Work Group","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27436"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.12029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.12029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:17:11Z","timestamp":1697275031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.12029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,25]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/nep.12029"],"URL":"https:\/\/doi.org\/10.1111\/nep.12029","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,25]]},"assertion":[{"value":"2013-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}